Recently, mutations in several genes have been described to be associated with sporadic ASD, but some genetic variants remain to be identified. The aim of this study was to use whole-exome sequencing (WES) combined with bioinformatics analysis to identify novel genetic variants in cases of sporadic congenital ASD, followed by validation by Sanger sequencing.
Background
Atrial septal defect (ASD) is the most common subtype of congenital heart disease (CHD), and its prevalence can reach between 8.93-10.6 per 1,000 live births in China [1, 2] . ASD can lead to several clinical complications, including infective endocarditis, chronic heart failure, and repeated lung infection, which can severely affect the physical and psychological health of affected patients [3] . The process of cardiac development is regulated by several genes and is precisely controlled; any disruption in cardiac development can cause congenital cardiac defects. Gene mutations have been shown to play important roles in the etiology and pathogenesis of ASD, including mutations in NKX2-5, GATA4, MYH6, and TBX5 [4, 5] . However, some genetic variants associated with sporadic ASD remain to be identified.
Whole-exome sequencing (WES) is a powerful and efficient tool to obtain sequencing information on the whole exome with high resolution and low cost [6] . Due to the limitations in current knowledge of the genomic noncoding regions, many recent studies have only focussed on the identification of pathogenic mutations in protein coding regions by using WES [7] . The rapid development in the techniques used in WES has shed light on the complex mechanisms involved in several forms of CHD, including patent ductus arteriosus (PDA), familial ASD, and ventricular septal defect (VSD) [8] . However, few studies have studied the mutations associated with the etiology and pathogenesis of sporadic ASD. Therefore, there is a need to extend studies on the spectrum of ASD-related mutations using WES and to provide a foundation for further functional analysis, which may further clarify the gene associations, the pathogenesis, and possibly lead to new diagnostic markers for sporadic ASD.
The aim of this study was to use WES combined with bioinformatics analysis to identify novel gene variants in cases of sporadic congenital ASD, followed by validation by Sanger sequencing and a multiplexed MassARRAY system.
Material and Methods

Study participants and collection of tissue samples
All participants in this study were from the Chinese population and were enrolled by the Department of Cardiovascular Surgery of Yan'an Affiliated Hospital of Kunming Medical University. Five Han patients with secundum atrial septal defect (ASD) were recruited, and their tissue samples were collected for whole-exome sequencing (WES). To confirm the WES findings, verification was conducted by Sanger sequencing with tissue samples and blood samples from the same five patients with sporadic ASD. For further evaluation, 452 additional patients with sporadic secundum ASD (212 male and 240 female patients) and 519 healthy subjects (252 male and 267 female subjects) were recruited, and the blood samples were obtained for further verification using a multiplexed MassARRAY system. The study was approved by the Medical Ethics Committee of Kunming Medical University. Informed consent was signed by each study participant or their legal guardians to participate in the study. The diagnosis of the ASD was based on echocardiography and during routine surgery for ASD surgical repair. Details of the clinical characteristics of the study participants are shown in Supplementary Table 1 .
The clinical data of the five patients with isolated ASD Case 1: A female patient aged 6 months was found to have a grade 3/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 22 mm.
Case 2: A male patient aged 13 months was found to have a grade 2/6 systolic murmur in the second left parasternal space. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 10 mm.
Case 3: A female patient aged 19 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-toright shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 16 mm.
Case 4: A female patient aged 23 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-toright shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 12 mm.
Case 5: A male patient aged 17 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 11 mm.
The secundum ASD of the five patients with isolated ASD was further confirmed during the ASD repair surgery, performed through a median sternotomy, under cardiopulmonary bypass. Atrial septal tissue samples from the five patients with ASD were collected from the rims of the defect in the atrial septum. The collected tissue samples were stored at -80°C. Serum was extracted from blood and stored at -80°C.
None of the five patients had a family history of congenital heart disease (CHD), Down's syndrome, or Marfan's syndrome. Patients with other common developmental defects or chromosomal abnormalities were excluded from this study. The 519 healthy subjects were recruited from the Department of Health Examination Centers of Yan'an Affiliated Hospital of Kunming Medical University. Echocardiograms, dynamic electrocardiograms, treadmill exercise tests, measurements of blood pressure and blood lipids were performed to exclude cardiovascular disease, including coronary artery disease, hypertension, and arrhythmias.
Whole-exome sequencing
Genomic DNA of tissue samples from five patients with ASD was extracted using Thermo DNA and the Lab-Serv Cell and Tissue DNA Extraction Kit (Thermo Scientific). The purity and quality of DNA from the samples were evaluated using an ultramicro-spectrophotometer (SpectraMax QuickDrop), and the optical density (OD) value of DNA was identified as between 1.8-2.0. Then the DNA was aliquoted and preserved in 0.5mL Eppendorf tubes at -80°C for WES. The enrichment of exon was performed by Agilent Sure Select Human All Exon V5 Kit (Agilent, USA) from 1.0 ug genomic DNA according to the manufacturer's protocol. First, the genomic DNA was broken randomly into 150-200bp fragments. Then, the DNA libraries were prepared by the addition of "A" bases to the 3' end of the DNA fragment. Finally, the DNA libraries were assessed for quality control and sequenced by Illumina Hiseq 2500 Sequencer (Supplementary Figure 1) .
Mapping to reference sequences
All single nucleotide variants (SNVs) of each sample were obtained by comparing the valid sequencing data with the human reference genome (UCSC Genome Browser hg19) using Burrows-Wheeler Aligner (BWA) software [9] to gain the primary mapping results. Then, the aligned data were sorted by SAMtools [10] to select the best mapping positions, and the duplicated reads were marked by Picard (http://sourceforge.net/ projects/picard/) so that they could be used in the next analysis.
Annotation, data filtering, and gene ontology analysis Functional annotation was conducted to find the genetic variation associated with ASD. First, all variants were annotated using the ANNOVAR software tool [11] . Then, the normal population variant databases, including 1,000 Genomes Project (version 2012), the Single Nucleotide Polymorphism database (DbSNP) (version 138), and the National Heart, Lung, and Blood Institute (NHLBI) database, were performed to exclude the common variations occurring with no more than 1% minor allele frequency (MAF) and variants not related to congenital heart disease (CHD). Then, the rare variants obtained in the previous step were further analyzed using the Venn analysis, gene ontology (GO) analysis, and literature review and protein database (http://www.uniprot.org/ and http://www.genecards. org/) to classify the variants associated with cardiac development or ASD. GO analysis was applied to analyze the main function of SNVs according to the GO which was the key functional classification of the National Center for Biotechnology Information (NCBI). The genes of the Gene Ontology (GO) term enrichment analysis included the following: GO.0048739_ cardiac muscle fiber development, GO.0003143_embryonic heart tube morphogenesis, GO.0003300_cardiac muscle hypertrophy, GO.0001539_cilium or flagellum-dependent cell motility, GO.0055008_cardiac muscle tissue morphogenesis, GO.0060038_cardiac muscle cell proliferation, GO.0060956_en-docardial cell differentiation, GO.0007512_adult heart development, GO.0003007_heart morphogenesis and GO.0030509_ BMP signaling pathway.
Candidate susceptible variants and gene selection
The SIFT [12] , PolyPhen-2 [13] and MutationTaster [14] were performed to predict whether the substitution of amino acid affected the function of the protein. Based on the degree of CHD, the mutation was selected as candidate susceptible variant if one of the three software showed it was pathological. Subsequently, the expression level of the corresponding genes of the candidate variants was selected via genecards (http:// www.genecards.org).
Variant validation and statistical analysis
Mutation validation was initially conducted by Sanger sequencing. Sanger sequencing was performed using genomic DNA from both tissue samples and peripheral blood of the same five patients with ASD recruited for WES. The mutations in both tissue samples and blood samples were selected as positive variants. Additionally, the positive variants were consistent with corresponding data from WES and were further tested using the multiplexed MassARRAY analysis in largescale samples. The primers involved in MassARRAY were designed using AssayDesigner 3.1. The sequences of the primers are listed in Supplementary Table 2 .
The genomic DNA was amplified under the following conditions: initial denaturation, 94°C for 15 min, then 45 cycles of 94°C for 20 s, 56°C for 30 s and 72°C for 60 s, followed by 72°C for 3 min. The final products were preserved at 4°C for Shrimp alkaline phosphatase (SAP) purification reaction to remove unincorporated dinucleotide triphosphates (dNTPs). The products were purified under the following conditions: 37°C for 40 min, 85°C for 5 min, the products were preserved at 4°C for extension polymerase chain reaction (PCR).
The conditions of extension PCR were listed as follows: 94°C for 30 s, 94°C for 5 s, then 40 cycles of 52°C for 5 s, 5 cycles of 80°C for 5 s, followed by 72°C for 3 min. The final products were preserved at 4°C for further analysis. The products and water were robotically dispensed into 384 sample plate and mass spectra were collected by the multiplexed MassARRAY compact matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) analyzer. The MassARRAY analysis was performed by EpiTYPER (Version: 4.0). The frequencies of the mutations were calculated by the c 2 test or Fisher exact test using SPSS version 22.0 (IBM, USA). P<0.05 represented statistical significance.
Results
Clinical characteristics of five patients with sporadic atrial septal defect (ASD)
Five patients with secundum atrial septal defect (ASD) diagnosed by echocardiogram were recruited into the study. The diameter of the defects in the atrial septum ranged from 10 mm to 22 mm (Table 1) . Except for ASD, other cardiac structural abnormalities and congenital anomalies were not found in these five patients. ASD was not diagnosed in other family members, which ensured that all patients included in this study had sporadic ASD.
Overview of whole-exome sequencing (WES) data
The total raw reads of ASD samples ranged from 17.57-28.46 million. More than 95% of the sequenced bases showed a quality score of ³Q20. The raw sequencing data yielded an average of 5000 Mb of effective data and the average depth of the target areas was over 60 × coverage. The quality and depth of target areas are listed in Supplementary Figure 2 and Supplementary Table 3. In total, 181,762 genomic variants in five samples from patients with isolated ASD were identified. There were an average of over 20,000 heterozygous variants and 15,000 homozygous variants in the samples (Supplementary Table 4 ). The circos map is shown to demonstrate the distributions of the variants on the chromosomes (Supplementary Figure 3) .
Identification of 33 ASD-associated gene variants by bioinformatics analysis
The advanced bioinformatic analysis was performed to identify the single nucleotide variants (SNVs) associated with ASD ( Figure 1 ). The 181,762 SNVs from the five patients were filtered by 1,000 Genome, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) database. After filtering, there were 713 rare variants, and the distribution of the rare variants on chromosomes was presented by circus map (Supplementary Figure 3,  Supplementary Table 4) . Furthermore, through performing Venn analysis, GO analysis and literature review, 13, 21 and 20 pathogenic variants perhaps involved in heart development were obtained (Supplementary Figure 4 , Supplementary Tables  5-7) . Also, the genes that overlapped and or were only minimally expressed in the heart were excluded from the present study. Finally, 33 variants in 25 genes were chosen for further analysis (Table 1) .
Validation and exploration of novel ASD variants
The 33 ASD-associated variants selected in the above step were further validated by Sanger sequencing in samples from the atrial septum and the peripheral blood (Supplementary Figure 5) . The findings showed that the mutations of 33 loci were consistent with corresponding data from WES, verifying the accuracy and reliability of WES findings. The consistency of mutations in tissue samples and blood samples not only confirmed our results but also excluded somatic mutations. Then, the multiplexed MassARRAY analysis was performed to verify the 33 variants in additional 452 samples from patients with ASD, and 519 samples from healthy subjects.
The results showed that nine variants were positive mutations, which were respectively located in nine genes. Table 2 ). The location of the three variants was found to be in located in a region that is highly conserved among species (Supplementary Figure 6) . Figure 1 . Schematic representation of the study design and protocol. First, all variants were annotated using the ANNOVAR bioinformatics software. The normal population variant databases, including 1,000 Genomes Project, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) databases were used to exclude the common variants occurring with more than 1% minor allele frequency (MAF). Second, the rare variants obtained in the previous step were further analyzed using Venn analysis, gene ontology (GO) analysis, and literature review. Third, three function predictor scores, SIFT [12] , Polymorphism Phenotyping v2 (PolyPhen-2) [13] , and MutationTaster [14] were used to predict whether the substitution of amino acids affected the function of the protein, and 33 single nucleotide variants (SNVs) were selected and validated as positive mutations by Sanger sequencing. Finally, a multiplexed MassARRAY system was performed to verify the 33 variants and three mutations with high mutation frequency, which were found to be strongly associated with atrial septal defect (ASD) (P<0.05).
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Discussion
The etiology of congenital heart disease (CHD), including atrial septal defect (ASD), is complex and associated with both environmental and genetic factors. Epidemiological data has shown that environmental factors, including viral infection during pregnancy, can increase the risk of CHD, but that the genetic causes are mainly associated with CHD [15] . The role of genomic variants in CHD, with rare mutations in cardiac genes, are more likely to result in CHD, including in sporadic ASD [4, 5] . Therefore, the aim of this study was to use wholeexome sequencing (WES) combined with bioinformatics analysis to identify novel genetic variants in cases of sporadic congenital ASD, followed by validation by Sanger sequencing.
In the present study, 181,762 genomic variants were identified by the WES approach. To the best of our knowledge, this is the first study to identify exon mutations associated with ASD by WES in sporadic ASD. Through verification by Sanger sequencing and MassARRAY, three loci were identified, 138665410 in the FOXL2 gene, 71098693 in the HYDIN gene, and 23862952 in the MYH6 gene, with high mutation frequency, likely to be associated with ASD. Also, two variants, 138665410 (NM_023067_c.C155G) in the FOXL2 gene and 71098693 (NM_001198542: c.A2207C) in the HYDIN gene were identified for the first time in ASD. The following variants, 138665410 (NM_023067_c.C155G) in the FOXL2 gene and 23862952 (NM_002471: c.G2851T) in the MYH6 gene were only found in ASD in this study. These findings probably represent disease-associated mutations for sporadic ASD.
The FOXL2 gene acts as an important transcription factor belonging to the winged helix/forkhead transcription factor family, including Foxa2, Foxc1/c2 and Foxos [16] . These family members have been identified as crucial components of the signaling pathways for controlling cardiogenesis and embryonic cardiac development [16] . Previous studies have shown that FOXL2 protein was expressed in several tissues, including the heart [16] [17] [18] [19] . However, the role of the FOXL2 gene has not been well studied in ASD. In the present study, we found that the mutation frequency of 138665410 variant (NM_023067_c. C155G) in FOXL2 gene was 26.11%, the G>C mutation was found in 118 cases with ASD but not in healthy subjects. The mutation frequency was significantly different between patients with ASD and healthy subjects (P<5×10 -4 ). The variant in FOXL2 that resulted in a replacement of alanine by glycine might affect atrial septum morphogenesis. The mechanism of the involvement of FOXL2 in ASD remains to be elucidated.
Previously published studies have shown that the activation of aberrant Notch signaling was induced the down-regulation of FOXL2 expression during the development of the eyelid levator muscle [20] . Also, the Notch signaling pathway has been shown to participate in the development of the heart, while abnormal Notch signaling might cause aberrant atrioventricular canal, proximal outflow tract and coronary system development [21, 22] . Therefore, it may be speculated that the function of FOXL2 during atrioventricular canal and proximal outflow tract formation is Notch signaling-dependent, but the specific mechanisms of FOXL2 mutations participating in the ASD development require further investigation.
The MYH6 gene encodes the alpha heavy chain subunit of cardiac myosin, which is a fast ATP-ase that is primarily expressed in atrial tissue, and plays a crucial role in muscle contraction and sarcomeric structure, with studies showing that aberrant expression of MYH6 ablated the atrial septal formation, and mutation of MYH6 contributed to ASD development [23] [24] [25] . In the present study, the 23862952 variant of the MYH6 gene (NM_002471: c.G2851T) was found in patients with ASD but not in healthy subjects (P<5×10 -4 ). The mutation was localized in the 22 nd exon of MYH6 gene, which resulted in a shift of the open reading frame (ORF), termination of protein synthesis, and loss of 988 amino acids by the premature stop codon. Due to this variant, a highly conserved amino acid was altered in the myosin tail domain, which led to the loss of about 95% of tail domains of MYH6. This mutation in the MYH6 gene might affect the development of the atrial septum, explaining its involvement in the pathogenesis of ASD.
The HYDIN gene is localized on the chromosome 16 (16q22.2) and encodes an axonal and cilial protein [26] . This gene has been predominantly found in the fetal heart and bronchial ciliated epithelia [27] , and mutations in the HYDIN gene have been shown to impair ciliary motility in a mouse model [28] . A large-scale mouse mutagenesis screening study showed that primary cardiac cilia were required in formation and development of endocardial cushions during embryogenesis [29] . A high rate of ciliary dysfunction and mutations in cilia-related pathways have also been identified in mice with cardiac defects [29] . However, the role of the HYDIN gene has not previously been well studied in human ASD. However, in this study, a novel mutation, the 71098693 variant (NM_001198542: c.A2207C) in the HYDIN gene was identified in patients with ASD, and its mutation frequency was significantly different between patients with ASD compared with healthy subjects (P<0.05). This variant caused a replacement of alanine by cysteine with charge modification, which may result in the mutation in the HYDIN gene disabling ciliary motility that affects the formation of endocardial cushions in cardiac embryogenesis. However, the exact function of HYDIN during atrial septum morphogenesis remains unknown.
Genomic studies rely on precision, reliability, and reproducibility with reliable methods of identification and analysis. In the current study, a combination of WES and generation sequencing was used to reduce the risk of false-positive results. In the selection of susceptible and reliable genetic variants related to ASD, the study design included five main steps. To exclude the interference of familial and syndromic ASD, sporadic cases of ASD were included. The use of WES yielded an average of 5000 Mb of data and the average depth of the target area was >60× coverage, with more than 95% of the sequenced bases shown to have a quality score of ³Q20, reflecting the accuracy of sequencing and the quality of samples in the study. The process of gene mutation filtering was performed as rigorously as possible, using the 1,000 Genomes Project, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) databases to exclude the common variants occurring with more than 1% minor allele frequency (MAF). Through a series of analyses that included Venn analysis, gene ontology (GO) analysis, and literature review, and the use of three predictive bioinformatics software programs, including SIFT [12] , PolyPhen-2 [13] , and MutationTaster [14] , it was possible to classify the variants associated with cardiac development or CHD and their potential impact on the function of proteins. To exclude false-positive variants, Sanger sequencing was performed, which showed that mutations from 33 loci were consistent with corresponding data from WES, which verified the accuracy and supported the reliability of the WES findings. Finally, the fifth important consideration in the study design was confirmation of the findings based on validation using large-scale clinical populations with ASD by using multiplexed MassARRAY analysis.
This study had several limitations. Because WES allowed the amplification of between 80-90% of all coding exons, some gene exons may have been missed in the process of sequencing. Also, WES cannot be performed to identify deep intronic mutations and is not an effective method to test for large genomic events, such as gene deletions and insertions.
Conclusions
The present study was the first study that demonstrated variants in the FOXL2 and the HYDIN genes were associated with sporadic atrial septal defect (ASD), and supported the use of whole-exome sequencing (WES), Sanger sequencing, and bioinformatics analysis to identify disease-associated mutations. The results showed that mutations in the FOXL2, MYH6 and HYDIN genes were associated with cases of ASD and that the presence of mutations in the FOXL2, MYH6, and HYDIN genes might contribute to the etiology of sporadic cases of ASD. 
